

Control and surveillance of human African trypanosomiasis

Report of a WHO Expert Committee

*This report contains the collective views of an international group of experts and
does not necessarily represent the decisions or the stated policy of the World Health Organization*



**World Health
Organization**

Contents

Abbreviations and acronyms	viii
WHO Expert Committee on control and surveillance of human African trypanosomiasis	ix
1. Introduction	1
2. Epidemiology of human African trypanosomiasis	3
2.1 Two diseases, two parasites, two epidemiological patterns	3
2.2 Transmission cycle	4
2.2.1 Gambiense human African trypanosomiasis	4
2.2.2 Rhodesiense human African trypanosomiasis	5
2.3 Reservoirs of infection	6
2.3.1 Gambiense human African trypanosomiasis	6
2.3.2 Rhodesiense human African trypanosomiasis	7
2.4 Risk factors for infection	10
2.4.1 Gambiense human African trypanosomiasis	10
2.4.2 Rhodesiense human African trypanosomiasis	12
2.5 Trends in numbers of cases reported	13
2.5.1 Gambiense human African trypanosomiasis	13
2.5.2 Rhodesiense human African trypanosomiasis	17
2.6 Geographical distribution and population at risk	19
2.7 Global environmental change	27
2.8 References	27
3. The parasite	42
3.1 Taxonomy of human infectious African trypanosomes	42
3.2 Morphology and cell structure	44
3.3 Life-cycle	46
3.4 The <i>Trypanosoma brucei</i> genome	49
3.5 Immune evasion	51
3.6 Biochemistry and modes of drug action	52
3.7 Drug resistance	53
3.8 References	55
4. The vector	62
4.1 Classification	63
4.1.1 Subgenus <i>Nemorhina</i>	65
4.1.2 Subgenus <i>Glossina</i> s. str.	65
4.1.3 Subgenus <i>Austenina</i>	66
4.2 Reproductive system	66
4.3 Reproduction	67
4.4 Lifespan and population dynamics	69
4.5 Diet	70
4.6 Geographical distribution of the main vector species	71
4.6.1 Vector species of the <i>Nemorhina</i> subgenus	72
4.6.2 Vector species of the <i>Glossina</i> s. str. subgenus	73
4.6.3 Vector species of the <i>Austenina</i> subgenus	74

4.7	Tsetse flies in their natural environment	74
4.7.1	Main habitats	74
4.7.2	Movements	76
4.7.3	Looking for hosts	76
4.7.4	Feeding preferences	77
4.7.5	Activity cycles	78
4.7.6	Dispersal	78
4.7.7	Resting places	79
4.8	Population genetics and geometric morphometrics	79
4.9	Genomics of tsetse flies	80
4.10	Tsetse flies as cyclical vectors	81
4.11	Vector control strategies	82
4.11.1	Control	82
4.11.2	Eradication	82
4.11.3	Preliminary surveys	83
4.12	Tsetse fly control methods	83
4.12.1	Bush clearing	83
4.12.2	Elimination of wild animal hosts	84
4.12.3	Biological control of tsetse flies	84
4.12.4	Autonomous control of tsetse flies	84
4.12.5	Indigenous tsetse fly control practices	84
4.12.6	Ground and aerial insecticide spraying	84
4.12.7	Protecting zero grazing units by insecticide-impregnated netting	85
4.12.8	Bait methods	87
4.12.9	Olfactory baits (attractants) for tsetse flies	89
4.12.10	Live baits	89
4.12.11	Sterile insect technique	91
4.13	New developments and outlook	91
4.14	References	92

5. The disease 103

5.1	Gambiense human African trypanosomiasis: clinical signs and symptoms	103
5.1.1	Lymphadenopathy	103
5.1.2	Fever	104
5.1.3	Headache	104
5.1.4	Pruritus	104
5.1.5	Musculoskeletal pain, hepatomegaly and splenomegaly	104
5.1.6	Cardiac involvement	104
5.1.7	Gastrointestinal symptoms	105
5.1.8	Oedema	105
5.1.9	Sleep disorder	105
5.1.10	Neuropsychiatric symptoms and signs	105
5.1.11	Endocrine disorders	106
5.2	Rhodesiense human African trypanosomiasis: clinical signs and symptoms	108
5.3	Specific groups	108
5.3.1	Children	108
5.3.2	HIV-coinfected patients	109
5.3.3	Human African trypanosomiasis in nonendemic countries	109
5.4	Sequelae	110
5.5	References	110

6. Diagnosis	118
6.1 Diagnosis of gambiense human African trypanosomiasis	119
6.1.1 Antibody detection	119
6.1.2 Parasite detection	123
6.1.3 Molecular detection	126
6.2 Diagnosis of rhodesiense human African trypanosomiasis	128
6.2.1 Antibody detection	128
6.2.2 Parasite detection	128
6.2.3 Molecular detection	129
6.3 Disease stage determination	130
6.3.1 White blood cell count	131
6.3.2 Parasite detection in cerebrospinal fluid	132
6.3.3 Other staging markers	132
6.3.4 Molecular tests	132
6.4 Treatment outcome assessment	132
6.5 Quality control of diagnostic testing	135
6.6 New developments and outlook	135
6.7 References	137
7. Treatment	150
7.1 Pharmacology of drugs for treatment of first-stage human African trypanosomiasis	153
7.1.1 Pentamidine	153
7.1.2 Suramin	155
7.2 Pharmacology of drugs for treatment of second-stage human African trypanosomiasis	157
7.2.1 Melarsoprol	157
7.2.2 Eflornithine	160
7.2.3 Nifurtimox	161
7.3 First-line treatment	162
7.3.1 First-stage gambiense human African trypanosomiasis: pentamidine	162
7.3.2 First-stage rhodesiense human African trypanosomiasis: suramin	163
7.3.3 Second-stage gambiense human African trypanosomiasis: nifurtimox– eflornithine combination therapy	164
7.3.4 Second-stage rhodesiense human African trypanosomiasis: melarsoprol	165
7.4 Alternative treatments for second-stage gambiense human African trypanosomiasis	167
7.4.1 Eflornithine monotherapy	167
7.4.2 Melarsoprol	167
7.5 Treatment in pregnancy	168
7.6 New developments and outlook	168
7.6.1 Preclinical and clinical developments	168
7.6.2 Research on other compounds	171
7.7 References	172
8. Control and elimination	189
8.1 Detection of cases of gambiense human African trypanosomiasis	189
8.1.1 Active case detection	190
8.1.2 Passive case detection	191
8.1.3 Management of parasitologically unconfirmed seropositive cases	192
8.2 Detection of cases of rhodesiense human African trypanosomiasis	193
8.2.1 Active case detection	194

8.2.2	Passive case detection	194
8.3	Control of animal reservoirs	195
8.3.1	Control in the domestic livestock reservoir	195
8.3.2	Control in the wildlife reservoir	196
8.4	Vector control	196
8.4.1	Methods	196
8.4.2	Traps and screens	196
8.4.3	Insecticide-treated cattle for control of rhodesiense human African trypanosomiasis	197
8.4.4	Implementation of vector control	198
8.5	Elimination of gambiense human African trypanosomiasis	199
8.5.1	Rationale	199
8.5.2	Concept of elimination, indicators and benchmarks	200
8.5.3	Strategies for elimination	201
8.5.4	Challenges	204
8.6	Elimination of rhodesiense human African trypanosomiasis	204
8.7	References	205
9.	Recommendations	215
	Acknowledgements	219
	Annexes	220
	Annex 1	
	Wild animal species documented as serving as hosts for <i>Trypanosoma brucei rhodesiense</i>	220
	Annex 2	
	Distribution of human African trypanosomiasis in West Africa	222
	Annex 3	
	Distribution of human African trypanosomiasis in Central Africa	223
	Annex 4	
	Distribution of human African trypanosomiasis in East and south-eastern Africa	224
	Annex 5	
	Cryostabilization	225
	Annex 6	
	Trap types used to capture various species of tsetse fly	226
	Annex 7	
	Protocol for storing blood samples on filter paper discs	228
	Annex 8	
	Storage of blood samples in AS1 buffer	231

Annex 9

Preparation of guanidine hydrochloride–ethylene diamine tetraacetic acid (EDTA) buffer	232
--	-----

Annex 10

Protocol for storage of blood samples in guanidine hydrochloride–ethylene diamine tetraacetic acid (EDTA) buffer	233
--	-----

Annex 11

Example of a field algorithm for diagnosis of <i>Trypanosoma brucei gambiense</i> infection	234
---	-----

Annex 12

Strategy for the elimination of gambiense human African trypanosomiasis in foci with high or moderate transmission (annual incidence > 1 case per 10 000 inhabitants in previous 5 years)	235
---	-----

Annex 13

Strategy for the elimination of gambiense human African trypanosomiasis in foci with low transmission (annual incidence > 1 case per 1 000 000 and < 1 case per 10 000 inhabitants in previous 5 years)	236
---	-----

Annex 14

Strategy for the elimination of gambiense human African trypanosomiasis in foci with no cases reported in previous 5 years	237
--	-----